Find the book here: https://www.barzilaiconsulting.com/fols
IT’S OUT.
100+ contributors. 3 volumes. More than 1,600 pages. Frontiers of Longevity Science is now available from Springer Nature, a landmark academic treatment of aging biology, longevity therapeutics, and the science, technology, and policy of life extension. I served as one of four Co-Editors with Max Rangeley, Regina R. M., and David Wood. I co-authored a foreword to Volume 1 with David A. Sinclair, wrote its preface, and contributed a chapter titled “Longevity Medicine: Evidence-Based Best Practices.” Additional forewords from Jamie Justice, Ph.D., Nir Barzilai, Wei-Wu He, Ph.D. (He/him), S. Jay Olshansky, Ph.D., Martin Borch Jensen, Alexander Fleming and Thomas Seoh, Dan Belsky, and Coleen Murphy. A glimpse of what readers will find. Biology and theories of aging • Aubrey de Grey’s 25-year retrospective on the damage-repair approach • Greg Fahy on thymus regeneration to reverse immunosenescence today • Michael Levin and Léo Pio-Lopez on longevity from cells to embodied minds • Yuri Deigin on aging as an evolved, centrally coordinated program Longevity medicine and the therapeutic pipeline • Nir Barzilai on four FDA-approved drug classes as today’s gerotherapeutics • Valter Longo and Sebastian Brandhorst on nutrition as the context for geroprotectors • Dudley Lamming on rapamycin as geroscience’s most reproducible geroprotector • Christin Glorioso, MD PHD and Justin Taylor on brain aging as quantifiable and modifiable Transformational technologies • Alex Zhavoronkov and Dominika Wilczok on AI’s Model Era and engineering Peakspan • Vittorio Sebastiano on partial reprogramming making aging malleable • Matthew “Oki” O’Connor on vascular aging as structural damage needing direct repair • Robert Freitas on Nanomedically Engineered Negligible Senescence • Damian Allis on diamondoid nanostructures as the near-term APM platform Economics, policy, and the future of longer lives • S. Jay Olshansky, Ph.D. on why framing aging itself as a disease is the wrong fight • James Peyer, PhD’s three-horizon strategy for the first regulated gerotherapeutic • Sonia Arrison on the 8% of NIA budget that funds basic aging biology • Keith Comito on cultural scripts that distort actual public support for life extension The series also covers senotherapeutics, mitochondrial and stem cell interventions, the human exposome, drug discovery robotics, cryonics, longevity capital and cities, lobbying, and the moral case for prioritizing this work. Earlier this year I served as Medical Editor of Harvard Medical School’s first Special Health Report on Longevity. Frontiers of Longevity Science is its academic counterpart.
More on the series: LinkedIn
Across these threads, which area do you see delivering the most practice-changing breakthrough this decade?
More from Volume 1, the biology of life extension: Michael Ringel on optimization theories like disposable soma as the only ones matching the evidence Peter Lidsky and team reopening the case for programmed aging Steven Garan re-centering the hypothalamus as master regulator of life-history transitions Michael Rae on SENS Seven as a more direct longevity roadmap than the Hallmarks of Aging Christopher Bradley, Christopher de Solis, and Samin Sharifi on DNA damage and repair as the substrate of aging Mark Hamalainen with nine co-authors arguing replacement is the most near-term path to reversal Matthew Scholz, Rob Shekoyan, and Alyson Harvey on genetic medicine as the only modality that adds new biological function Brennan Stadler, Nivedita Nambrath, Rituparna Ghosh, and invited lead Matt Yousefzadeh on senescent cells and senotherapeutics Andy Lee and Bahareh Behrouz on mitochondrial interventions for resilience and function Yuta Lee and Jau-Nan Lee on stem cell-derived exosomes as a scalable rejuvenation platform Max Rangeley and Regina R. M. introducing eutropy as the unifying framework for longevity interventions…
More from Volume 2, the technological possibilities: Dr. Anmol Kapoor on the convergence of preventive medicine and consumer health Luisa Georgiana Bâcă, M.D., Gil Blander, and Bartek Nogal on precision longevity grounded in individual trajectories Mitchell Lee, Ben Blue, and Yan Ting Zhao on robotics and automation in longevity drug discovery Mark Hamalainen, Alexander German, Ramón Risco, and Ralf Spindler on reversible cryostasis Enrique Alcalá and Ramón Risco on ultrasound rewarming for organ-scale cryopreservation Tina Woods leading an interdisciplinary team on the human exposome as the integrated lens for aging Philippe GERWILL on the digital twin reconceived as a Longevity GPS for navigation under uncertainty Raiany Romanni-Klein, PhD on why less than 1% of NIH funding flowing to aging biology is a moral prejudice problem
From Volume 3, the future of extended lifespans (capital and infrastructure): Ethan Berg’s Competitive Advantage and Value Cascade framework applied to longevity biotech through seven case studies Marc P. Bernegger on the strategic role of longevity investing at this inflection point Boyang Wang @ Immortal Dragons on investing in high-risk, high-impact longevity companies as a public good Heather Carter on Capital, Culture, and Care as the three domains the longevity economy must redesign together Todd White on longevity science as national infrastructure on par with sanitation and vaccination José Luis Cordeiro mapping longevity cities from Singapore and Dubai to Próspera, Vitalia, Zuzalu, and Infinita Roman Bauer on a coordinated research ecosystem blueprint for radical longevity Dominik Thor president of the Geneva College of Longevity Science collaboration with Shahrukh Hashmi at the Department of Health Abu Dhabi introducing Responsible Longevity as the governance framework for the field Yu-Xuan Lyu (Lu), PhD and Richard Siow on geroscience driving the next era of nutraceuticals and pharmaceuticals.
The forewords across the three volumes form a connected case for the field: A second Nir Barzilai foreword on centenarian biology driving CETP, APOC3, and IGF-1 drug pipelines Wei-Wu He, Ph.D. (He/him) on Human Longevity, Inc.'s deployed platform: 12,000-plus longitudinal cohort and zero prostate cancer deaths among 5,000 men under care Jamie Justice, Ph.D.on what the $101M XPRIZEE Healthspan competition is doing as evidentiary infrastructure Alexander Flemingg and Thomas Seoh on Kitalys Institute’s regulatory and convening work, including the THRIVE Act Martin Borch Jensen on four fundamental constraints and why AI’s near-term contributions will come from diagnostics Dan Belsky on three generations of epigenetic clocks and where biomarker science goes next Coleen Murphy on expanded model organisms and AI as hypothesis generator, not biological truth David Wood closing the series with three scenarios for 2031 and nine trends that determine which one we get
